LY 3031207

Drug Profile

LY 3031207

Alternative Names: LY3031207

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Eli Lilly
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Unspecified

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Undefined(In volunteers) in USA (PO)
  • 09 Oct 2012 Eli Lilly terminates phase I trial in Healthy volunteers in USA (NCT01632566)
  • 30 Jun 2012 Eli Lilly initiates enrolment in a multiple-dose Phase-I trial in healthy volunteers in USA (NCT01632566)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top